Autopsy report · NCT04582409
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
Cause of deathFunding or business
“Terminated due to business decision”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 7 months before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Atrial Fibrillation
- Interventions
- HSY244; Placebo
- Participants
- 13
- Sites
- 4
- Countries
- Germany, United States
Trials that died the same way
- A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
“Terminated due to strategic business decision.” - Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
“Study terminated due to business decision” - A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
“Terminated prior to completion of accrual per corporate decision.” - Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study
“terminated due to administrative reasons.” - Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
“Study terminated due to business and strategic decision.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.